SOMERSET, N.J., Dec. 3, 2009 (GLOBE NEWSWIRE) -- inVentiv Health (Nasdaq:VTIV), a leading provider of commercialization services to the global pharmaceutical and healthcare industries, today announced the launch of FlightPath(TM), a customizable, interactive approach to commercialization planning.
FlightPath(TM) serves as an organizing platform that provides healthcare companies with access to strategic insights, planning expertise and tactical execution capabilities, all coordinated through a single point of contact. The FlightPath(TM) platform is based upon inVentiv's vast commercialization experience, which includes successfully launching or commercializing more than 800 pharmaceutical and life sciences products over the past decade across a variety of company types.
"Launching new products in today's complex market can be extremely daunting. Even the most innovative compounds can fail to achieve commercial success without well developed strategies, aligned tactics, and carefully coordinated execution," said Norman Stalsberg, President of inVentiv Advance Insights. "FlightPath(TM) is a tailored commercialization approach designed to help healthcare executives navigate the process with confidence, regardless of whether their product is still in early development, relaunching after being on the market for years, or somewhere in between."
FlightPath(TM) is structured around four key planning disciplines:
* Commercialization Strategy, which includes defining the business
opportunity, establishing positioning, and setting strategies,
goals, priorities and critical success factors;
* Commercialization Planning, which includes the construction of
the detailed cross-functional tactical plan, and encompasses
specific timelines and budgets, roles and responsibilities of
team members.
* Implementation, which includes execution of plan tactics through
inVentiv's seasoned teams of marketing and sales experts; and
* Monitoring and Reporting, which provides continuous progress
monitoring and feedback and the identification of necessary
planning modifications and adjustments.
"FlightPath(TM) is the only commercialization solution that is customized to address the unique challenges and opportunities facing each healthcare brand," said Mr. Stalsberg. "And unlike consultancies that develop strategic plans but cannot implement, inVentiv has a broad range of best-in-class capabilities across the product lifecycle that can be incorporated for all aspects of the plan development and execution. This is a significant advantage, particularly for smaller and emerging companies that have limited in-house resources."
Each FlightPath(TM) team is led by an inVentiv "co-pilot" who serves as the central point of contact for orchestrating and integrating all components of the plan. Co-pilots are seasoned inVentiv marketing professionals with an average of more than 20 years of industry experience and significant expertise in commercial plan development and execution.
To learn more about inVentiv Health's FlightPath, please contact Rebecca Hyde at rhyde@inventivhealth.com.
About inVentiv Health
inVentiv Health, Inc. (Nasdaq:VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com.
The inVentiv Health, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4942
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.